Serina Therapeutics, Inc.
$1.70+5.59%(+$0.09)
TickerSpark Score
48/100
76
Valuation
40
Profitability
10
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SER research report →
52-Week Range7% of range
Low $1.22
Current $1.70
High $7.92
Companyserinatherapeutics.com
Serina Therapeutics, Inc. , a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease.
- CEO
- Steven A. Ledger
- IPO
- 2000
- Employees
- 12
- HQ
- Huntsville, AL, US
Price Chart
-70.23% · this period
Valuation
- Market Cap
- $17.00M
- P/E
- -0.96
- P/S
- 130.77
- P/B
- 1.16
- EV/EBITDA
- 0.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 73.85%
- Op Margin
- -18803.08%
- Net Margin
- -16359.23%
- ROE
- -402.16%
- ROIC
- -116.63%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-19,182,000 · -72.17%
- EPS
- $-1.91 · -26.49%
- Op Income
- $-24,022,000
- FCF YoY
- -4.64%
Performance & Tape
- 52W High
- $7.92
- 52W Low
- $1.22
- 50D MA
- $1.93
- 200D MA
- $3.35
- Beta
- 0.04
- Avg Volume
- 3.34M
Get TickerSpark's AI analysis on SER
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Bailey Gregory | other | 59,667 |
| Mar 31, 26 | Venkatesan Jay | other | 7,553 |
| Mar 23, 26 | Moreadith Randall | other | 6,500 |
| Mar 23, 26 | Moreadith Randall | other | 6,500 |
| Mar 23, 26 | Moreadith Randall | sell | 6,500 |
| Mar 19, 26 | Moreadith Randall | other | 39,000 |
| Mar 19, 26 | Moreadith Randall | other | 39,000 |
| Mar 19, 26 | Moreadith Randall | sell | 39,000 |
| Feb 3, 26 | Moreadith Randall | other | 69,000 |
| Feb 3, 26 | Tenjarla Srini | other | 69,000 |
Our SER Coverage
We haven't published any research on SER yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SER Report →Similar Companies
GNTA-0.80%
Genenta Science S.p.A.
$0.62
SKYE+6.04%
Skye Bioscience, Inc.
$0.77
JUNS-35.94%
Jupiter Neurosciences, Inc.
$0.20
ALGS+8.11%
Aligos Therapeutics, Inc.
$5.60
BRNS+0.51%
Barinthus Biotherapeutics plc
$0.69
INMB+0.00%
INmune Bio, Inc.
$1.41
XFOR+3.57%
X4 Pharmaceuticals, Inc.
$3.77
TELO+7.38%
Telomir Pharmaceuticals, Inc. Common Stock
$1.31